ArticleFrontiers in immunology2026
Minocycline ameliorates CNS autoimmunity through restraint of CD4
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Minocycline is a tetracycline antibiotic with profound anti-inflammatory activity directed primarily against microglial cells and macrophages. Activation of nuclear factor erythroid 2-related factor 2 (Nrf2) is considered as an important target of minocycline. This drug has been considered a promising therapeutic for multiple sclerosis, an autoimmune disorder of the central nervous system (CNS). Still, its effect on CNS autoimmunity is not entirely understood. The aim of this study was to investigate the potency of short-term minocycline administration in fully developed CNS inflammation. To this end, an animal model for multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), was used and minocycline was applied at the peak of the disease. The treatment led to immediate reduction of EAE clinical signs, and also to reduction of overall EAE clinical course severity. The effect of minocycline at the peak of EAE was paralleled with inhibited NO and reactive oxygen species (ROS) production by immune cells in CNS. Interestingly, the reduction was specific for CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.